Lecia Sequist
Physician · Massachusetts General Hospital
Credentials: · · ·
History
- 2026–Present
2002–2005- 1995–1999
1991–1995
Research
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
New England Journal of Medicine · 2010 · 3,649 citations
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
Science Translational Medicine · 2011 · First of 22 authors · Corresponding · 2,891 citations
Journal of Clinical Oncology · 2013 · First of 20 authors · 2,727 citations
- ZP
50 papers · 13 as a fellow
- JE
47 papers · 1 as a fellow
41 papers
- DH
41 papers
39 papers
- SD
33 papers · 1 as a resident
- JG
31 papers · 3 as a fellow
30 papers
Grants
- 1997–2028
Training Program in Cancer Biology and Therapeutics
National Cancer Institute · T32
PI · $3.4M · Massachusetts General Hospital
- 2022–2027
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
National Cancer Institute · P50
PI · $11.4M · Dana-Farber Cancer Inst
- 2009–2027
Non-Genomic Resistance Mechanisms in EGFR-Mutant Lung Cancer
National Cancer Institute · R01
Contact PI · $2.8M · Massachusetts General Hospital
- 2024–2027
A Real-Time AI-Driven High-Throughput Proteomics Data Acquisition Method for Clinical Applications
National Cancer Institute · R61
PI · $702.7K · Massachusetts General Hospital
Clinical trials
- 2021–2025
Lung Cancer Risk and Early Detection in Firefighters
Principal investigator · Completed
Massachusetts General Hospital
- 2019–2026
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Principal investigator · Active not recruiting · Phase 2
AstraZeneca
- 2013–2017
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Principal investigator · Completed · Phase 2
Massachusetts General Hospital
- 2013–2021
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Principal investigator · Unknown · Phase 2
Massachusetts General Hospital